Try our Advanced Search for more refined results

Amgen Inc. et al v. Hospira, Inc.

  1. April 20, 2020

    Epogen IP Fight Ends With Hospira Paying More Than $70M

    Hospira Inc. has paid Amgen Inc. more than $70 million for infringing a patent covering its anemia treatment Epogen, after the Federal Circuit refused to grant Hospira any relief from a 2017 judgment. 

  2. August 27, 2018

    Hospira Can't Void Amgen's $70M Biosimilar Patent Win

    A Delaware federal judge on Monday refused to erase a $70 million patent infringement verdict against Hospira Inc. over its biosimilar version of Amgen Inc.'s anemia treatment Epogen, saying a jury reasonably found that a safe harbor for biosimilar development mostly didn't apply.

  3. October 24, 2017

    Amgen, Hospira Challenge $70M Biosimilar Judgment

    Hospira Inc. urged a Delaware federal court Monday to overturn a $70 million patent infringement verdict regarding Hospira's production of a biosimilar for Amgen Inc.'s anemia treatment Epogen, while Amgen argued the judgment should be even higher.

  4. October 12, 2017

    Amgen Defends $70M Biosimilar Verdict Against Hospira

    Amgen Inc. on Wednesday defended its $70 million patent infringement verdict against post-trial attacks from Hospira, telling a Delaware federal judge that a regulatory safe harbor for limited manufacturing of the anemia-targeting biosimilar is unavailable here.

  5. September 28, 2017

    Hospira Challenges Amgen's $70M Biosimilar Verdict

    Hospira Inc. on Wednesday attacked a $70 million jury verdict for patent infringement related to its proposed biosimilar of Amgen Inc.'s anemia drug Epogen, telling a Delaware federal judge that it is shielded by a safe harbor.

  6. September 22, 2017

    Amgen Gets $70M In Biosimilar Patent Suit Against Hospira

    A Delaware federal jury awarded Amgen Inc. $70 million in damages late Friday after finding that Hospira Inc. infringed a patent for the anemia treatment Epogen, rejecting Hospira's argument that it was protected by a safe harbor meant for companies seeking federal approval for biosimilar products.

  7. September 18, 2017

    Hospira Tells Jury Biosimilar Was Covered By Safe Harbor

    Pharmaceutical company Hospira Inc. told a freshly empaneled Delaware federal jury Monday that its production of a biosimilar version of an Amgen Inc. biologic anemia treatment doesn't infringe Amgen's patents because the product was just used for testing and regulatory purposes.

  8. September 08, 2017

    Amgen Set To Face Off With Hospira In Biosimilar IP Trial

    Pharmaceutical companies Amgen Inc. and Hospira Inc. are set to square off later this month in a patent infringement trial centering on Hospira's efforts to produce a biosimilar version of Amgen's anti-anemia drug Epogen after the sides completed their final pre-trial conference in Delaware on Friday.

  9. June 28, 2017

    Amgen, Hospira Battle Over Experts Ahead Of Patent Trial

    Pharmaceutical company Amgen Inc. sparred Wednesday in Delaware federal court with competitor Hospira Inc. over expert reports each side is hoping to use at a September patent infringment trial on Hospira's efforts to produce a biosimilar version of Amgen's anti-anemia drug Epogen.

  10. August 05, 2016

    Hospira Can't Beat Amgen's Biosimilar Notice Suit

    A Delaware federal judge on Friday refused to throw out Amgen’s suit accusing Hospira of improperly failing to provide 180-day notice of sales of a biosimilar version of anti-anemia blockbuster Epogen.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!